CAPR Stock UPDATES Capricor Therapeutics Inc. (CAPR) 4.0000 10/29/2014

New Post Public Reply Private Reply Replies (0) Message Board

Oct 29, 2014 at 10:19 AM

Capricor Therapeutics Inc. (CAPR) 4.0000 $CAPR

Capricor Therapeutics Announces Acquisition of Intellectual Property Rights to Family of Natriuretic Peptides From Medtronic, Inc.
GlobeNewswire - Tue Oct 14, 7:08AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has entered into an agreement to acquire patent rights from Medtronic, Inc. (NYSE:MDT) relating to the formulation and pump delivery of natriuretic peptides. Capricor recently announced that it plans to develop a clinical program using Cenderitide, a natriuretic peptide, for the treatment of post-acute heart failure.
MDT: 66.82 (+0.31)

Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation
GlobeNewswire - Thu Oct 09, 7:23AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it plans to develop a clinical program using Cenderitide for the treatment of post-acute heart failure using Insulet's drug delivery system based on the OmniPodinsulin management system.
PODD: 40.70 (-0.20)

Capricor Announces Plans to Pursue Clinical Program for the Treatment of Duchenne Muscular Dystrophy With Cardiosphere-Derived Cells (CDCs)
GlobeNewswire - Mon Oct 06, 6:11AM CDT
Capricor Therapeutics, Inc.(OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it plans to develop a clinical program for Duchenne Muscular Dystrophy (DMD) using CAP-1002, Capricor's lead product candidate. CAP-1002 is an allogeneic, off-the-shelf, investigational cell therapy derived from donor heart tissue and is infused directly into a patient's coronary arteries during a catheterization procedure. CAP-1002 is currently in Phase II clinical testing for adults with ischemic heart disease.

Capricor Presents Safety and Preliminary Efficacy Results From ALLSTAR Phase I Clinical Trial at TCT 2014
GlobeNewswire - Thu Sep 18, 7:27AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, presented an abstract entitled "ALLogeneic Heart STem Cells To Achieve Myocardial Regeneration (ALLSTAR): The Six Month Phase I Safety Results" with an oral presentation by Dr. Raj R. Makker, M.D., of Cedars-Sinai Medical Center, at the Transcatheter Cardiovascular Therapeutics (TCT) conference at the Walter E. Washington Convention Center, Washington, DC on September 16, 2014.

Capricor Therapeutics Reports Second Quarter 2014 Financial & Business Highlights
GlobeNewswire - Wed Aug 13, 9:19AM CDT
Reports Encouraging Results From Phase I of the ALLSTAR Clinical Trial and Signed Exclusive License With Cedars-Sinai Medical Center for Exosomes IP Portfolio

Capricor Therapeutics to Hold Second Quarter 2014 Business Update Conference Call on August 13, 2014 at 4:30 p.m. Eastern Time
GlobeNewswire - Mon Aug 04, 7:27AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics to prevent and treat heart disease, today announced that Company management will hold a conference call to discuss second quarter 2014 business highlights on Wednesday, August 13, 2014, at 4:30 p.m. ET.

Capricor Announces Encouraging Results From Phase I ALLSTAR Trial; Phase II Trial Underway
GlobeNewswire - Wed Jul 16, 6:59AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced today encouraging analysis of the completion of its MRI data at the six-month time point from Capricor's Phase I ALLSTAR trial.

Capricor Therapeutics to Present at the First Regenerative Medicine Forum at BIO International Convention
GlobeNewswire - Mon Jun 23, 8:03AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Dr. Linda Marbán, President and CEO, will present during a panel at the first, all-day Regenerative Medicine Forum organized by the California Institute for Regenerative Medicine (CIRM), in association with the Alliance for Regenerative Medicine (ARM) and the International Society for Stem Cell Research (ISSCR). The Regenerative Medicine Forum will take place on Wednesday, June 25, 2014 during the BIO International Convention being held June 23-26, 2014 in San Diego, California.

Capricor Therapeutics Speaks at Panel on Regulation of Stem Cell-Derived Therapeutic Products at DIA 2014 50th Annual Meeting
GlobeNewswire - Thu Jun 19, 12:28PM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Dr. Rachel Ruckdeschel Smith, Ph.D., Vice President of Research and Development at Capricor, participated in a panel discussion on the regulation of therapeutic products derived from human stem cells at the DIA 2014 50 Annual Meeting, being held June 15-19, 2014 in San Diego, California.

Capricor Therapeutics to Present ALLSTAR Phase I Trial Data at ACC Annual Meeting 2014
GlobeNewswire - Fri Mar 28, 12:42PM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics to prevent and treat heart disease, today announced Co-founder and Scientific Advisory Board Chairman, Dr. Eduardo Marbán, M.D., Ph.D., will present at the American College of Cardiology 63 Annual Scientific Session and Expo, taking place March 29-31, 2014 in Washington, DC. Dr. Marbán's presentation will highlight positive data demonstrating that the Phase I portion of the Company's ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR) Phase I/II trial met its primary endpoint of safety.

Capricor Therapeutics to Present at Two Upcoming Investor Conferences
GlobeNewswire - Mon Mar 10, 1:11PM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR) today announced that Chief Executive Officer Dr. Linda Marbán is scheduled to present at the 26 Annual ROTH Conference, being held March 9-12, 2014 in Dana Point, Calif., and the Alliance for Regenerative Medicine's 2 Annual Regen Med Investor Day on March 26, 2014 in New York, N.Y.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Luvme Hair Offers Wig Variety for Winter Fashion

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...